EXHIBIT 10.1

AMENDMENT NO. 3 TO
AGREEMENT AND PLAN OF MERGER

         THIS AMENDMENT NO. 3 TO AGREEMENT AND PLAN OF MERGER (this "Amendment")
is made as of this 15th day of April, 2003, among Bioanalytical Systems, Inc.,
an Indiana corporation ("BAS"), PI Acquisition Corp., a Maryland corporation
("MergerCo"), and PharmaKinetics Laboratories, Inc., a Maryland corporation (the
"Company"). All capitalized terms used but not defined herein shall have the
meanings assigned to such terms in the Merger Agreement (as defined below).

         WHEREAS, BAS, MergerCo and the Company are parties to that certain
Agreement and Plan of Merger dated as of June 20, 2002, as amended by Amendment
No. 1 to Agreement and Plan of Merger dated as of July 24, 2002 and Amendment
No. 2 to Agreement and Plan of Merger dated as of November 21, 2002 (the "Merger
Agreement"); and

         WHEREAS, BAS, MergerCo and the Company desire to amend certain portions
of the Merger Agreement pursuant to the terms and conditions of this Amendment;

         NOW, THEREFORE, in consideration of the mutual agreements herein
contained, and pursuant to Section 10.11 of the Merger Agreement, the Merger
Agreement is hereby amended by the parties as follows:

 
Section 9.1(b)(iii) is hereby amended by deleting the phrase "March 31, 2003";
and replacing it with "June 30, 2003".

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

         IN WITNESS WHEREOF, the undersigned have caused this Amendment to be
executed by their duly authorized officers as of the date first above written.

  BIOANALYTICAL SYSTEMS, INC.

By:  /s/ Peter T. Kissinger

--------------------------------------------------------------------------------

Peter T. Kissinger, Ph.D.
Chief Executive Officer

PI ACQUISITION CORP.

By:  /s/ Peter T. Kissinger

--------------------------------------------------------------------------------

Peter T. Kissinger, Ph.D.
Director

PHARMAKINETICS LABORATORIES, INC.

By:  /s/ James M. Wilkinson

--------------------------------------------------------------------------------

James M. Wilkinson, II, Ph.D.
President and Chief Executive Officer